Dr Hurvitz presents data at San Antonio Breast Cancer Symposium 2016 from the phase II neoMONARCH trial of abemaciclib, a CDK4/6 inhibitor, as a single agent or combined with anastrozole for post-menopausal women with HR , HER- breast cancer.

The study found that, alone or with anastrozole, abemaciclib induced significantly greater cell cycle arrest, defined by reduced Ki67 expression.

Dr Hurvitz spoke more on CDK4/6 inhibition at an ecancer symposium in Copenhagen, here.